Delving into the Latest Updates on Vitamin B2 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1-Deoxy-1-(7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2H)-yl)pentitol, 6,7-Dimethyl-9-D-ribitylisoalloxazine, 7,8-Dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)isoalloxazine

+ [27]

Target-

Action-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic DiseaseCongenital DisordersOther Diseases

Active Indication

Riboflavin DeficiencyMedium Chain Acyl CoA Dehydrogenase Deficiency

Inactive Indication

AstigmatismCorneal ectasiaHyperopia

Originator Organization-

Active Organization

iniuva

Inactive Organization

Glaukos Corp.

Drug Highest PhaseApproved

First Approval Date-

RegulationOrphan Drug (European Union), Priority Review (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC17H20N4O6

InChIKeyAUNGANRZJHBGPY-SCRDCRAPSA-N

CAS Registry83-88-5

Fusarium oxysporum f. sp. cubense (Foc) is a soil-borne pathogen that severely limits banana yields globally.In the present study, the Rasthali (AAB) banana cultivar was transformed with the Arabidopsis thaliana BAG4 gene, driven by a root-specific promoter, to modulate cell death pathways and induce resistance against the fungal pathogen.Stable transgenic plants were developed by transforming embryogenic cells derived from immature male floral buds.Integration and expression of the gene cassette in transformants were confirmed by Southern blotting and real-time PCR, resp.Stable transgenic banana lines were selected based on their copy number and vigorous growth.The root challenge bioassay of the selected lines showed a vascular discoloration index (VDI) ranging from 8 to 51%, compared to untransformed bananas, which exhibited a 97% VDI.Lines demonstrating tolerance were further micro-propagated for detailed anal.The enzyme activities of superoxide dismutase and peroxidase were higher in transformed lines than control plants.Addnl., the TUNEL assay of the stable transformant line 168 exhibited reduced apoptotic-like features in the roots post-Foc infection.The results indicated that AtBAG4 transgenic Rasthali plants exhibited tolerance to Foc (Race 1) by inhibiting cell death.Therefore, AtBAG4 gene-mediated tolerance in banana cv.Rasthali offers a promising and sustainable approach for the integrated management of Fusarium wilt in bananas.

01 Dec 2025·Current Pain and Headache Reports

Nutraceuticals and Headache 2024: Riboflavin, Coenzyme Q10, Feverfew, Magnesium, Melatonin, and Butterbur

Review

Author: Tepper, Stewart J ; Tepper, Katharine

PURPOSE OF REVIEWNutraceuticals are not regulated by the US Food and Drug Administration, so a careful literature review is essential to make clinical decisions. Riboflavin or vitamin B2 can be recommended for migraine prevention in adults, but pediatric use is not proven. Adverse events are minimal. Coenzyme Q10 has Level C evidence for migraine prevention and low adverse events. Feverfew may be effective for migraine prevention, but the absence of clear safety studies, the differences in doses and characteristics of dried leaf preparations, and the myriad of feverfew cellular effects suggest caution in recommendation for use. Magnesium is recommended for migraine prevention and intravenous acute use, with the potential for generally mild gastrointestinal tolerability adverse events. Melatonin has very low certainty for evidence of efficacy, and is weakly recommended in those with sleep problems. However, purity of US sold melatonin is very poor. Butterbur or petasites preparations have strong evidence for efficacy and concern for hepatotoxicity. Please see the US National Center for Complementary and Integrative Health/NIH online site https://www-nccih-nih-gov.libproxy1.nus.edu.sg/health/butterbur for up-to-date recommendations on whether to use this nutraceutical.

01 Jun 2025·Synthetic and Systems Biotechnology

Construction of antibiotic-free riboflavin producer in Escherichia coli by metabolic engineering strategies with a plasmid stabilization system

Article

Author: Du, Yuxuan ; Rao, Zhiming ; Wang, Kang ; Pan, Xuewei ; Zhang, Xiaoling ; Yin, Jilong ; Yang, Zhen ; Li, Yanan ; You, Jiajia

Riboflavin, an important vitamin utilized in pharmaceutical products and as a feed additive, is mainly produced by metabolically engineered bacterial fermentation. However, the reliance on antibiotics in the production process leads to increased costs and safety risks. To address these challenges, an antibiotic-free Escherichia coli riboflavin producer was constructed using metabolic engineering approaches coupled with a novel plasmid stabilization system. Initially, competitive pathways and feedback inhibition were attenuated to enhance the metabolic flux towards riboflavin. Key genes in the purine pathway were overexpressed to boost the availability of riboflavin precursors. Subsequently, a plasmid stabilization system based on toxin was screened and characterized, achieving a plasmid retention rate of 84.9% after 10 days of passaging. Finally, transcriptomic analysis at the genome-wide level revealed several rate-limiting genes, including pgl, gnd, and yigB, which were subsequently upregulated, leading to a 26% improvement in riboflavin production. With optimization of the culture medium, the final strain allowed the production of 11.5 g/L of riboflavin with a yield of 90.4 mg/g glucose in 5 L bioreactors without antibiotics. These strategies can be extended to other plasmid-based riboflavin derivative production systems.

6

News (Medical) associated with Vitamin B2

11 Feb 2025

·www.businesswire.com

TECLens Secures $9.3 Million Series A Funding to Advance Its Non-Invasive Refractive Technology

STAMFORD, Conn.--( BUSINESS WIRE )-- TECLens , Inc., a clinical-stage ophthalmic medical device company, announced today it raised $9.3 million in a Series A round co-led by Johnson & Johnson Innovation – JJDC Inc. and Yonjin Capital. Other investors include Rimonci Capital, and Sunmed Capital. The funding is allocated to support the clinical development of the company’s non-incisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea. “We're incredibly excited to garner investor support from both industry veterans and newcomers to the ophthalmology sector,” said Thomas Dunlap, CEO of TECLens. “This collective backing of our investors is a powerful endorsement of both our quantitative corneal cross-linking technology and our mission to deliver a non-invasive and cost-effective refractive treatment for millions of people with vision disorders. We're honored by their support and view this as a strong validation of our innovative approach to addressing both refractive and therapeutic unmet needs in eye care.” Traditional CXL uses riboflavin and ultraviolet light to strengthen the cornea. TECLens’ proprietary Quantitative Corneal Cross-Linking (qCXL™) is designed to deliver a pre-calculated pattern and dose of UV light based on a computational biomechanics model of each patient’s eye. The company’s proprietary CXLens ® device comfortably delivers the UV light and treatment progression in real-time with an on-board ultrasound sensor to ensure adherence to the pre-plan, enhancing precision. The CXLens ® device, designed for use in the exam room, has been successfully demonstrated in eyes with keratoconus. TECLens is now advancing clinical studies for refractive correction, with a primary focus on presbyopia. Potential future applications include pediatric progressive myopia, low-order adult myopia, hyperopia and astigmatism. “The TECLens qCXL™ technology has tremendous potential to improve access to care for some of the world’s most complex vision correction needs, including presbyopia, keratoconus, low-order myopia, hyperopia, and astigmatism,” said Dr. Roy Chuck, Chairman, Department of Ophthalmology, Montefiore Einstein and a pioneer of the foundational technologies behind TECLens. “TECLens’ approach to refractive correction is attractive to both patients and physicians and creates exciting possibilities for the future of the refractive market.” About TECLens, Inc. TECLens is a clinical-stage ophthalmic medical device company, pioneering non-invasive, personalized corneal cross-linking technology ( qCXL™ ) for vision correction. Our innovative CXLens ® system uses patterned ultraviolet (UV) light to gently reshape the cornea with continuous biomechanical control. qCXL™ is designed to be a comfortable, safe, and effective alternative to traditional refractive surgeries. TECLens’ breakthrough technology aims to set a new standard in precision, accessibility, and patient experience—redefining vision correction with innovation that improves quality of life. To learn more visit www.teclens.com and follow us on LinkedIn .

03 Sep 2024

·www.drugs.com

Global Study Reveals Widespread Micronutrient Deficiencies

TUESDAY, Sept. 3, 2024 -- More than 5 billion people globally do not consume enough iodine, vitamin E, and calcium, according to a study published online Aug. 29 in The Lancet Global Health . Simone Passarelli, Ph.D., from the Harvard T.H. Chan School of Public Health in Boston, and colleagues estimated micronutrient intake using a novel approach accounting for the shape of a population's nutrient intake distribution, based on dietary intake data from 31 countries. These distributions were applied to data for 185 countries for 34 age-sex groups to estimate the prevalence of nutrient intakes for 99.3 percent of the global population. The researchers found that more than 5 billion people do not consume enough iodine, vitamin E, and calcium (68, 67, and 66 percent of the global population, respectively). More than 4 billion people do not consume enough iron, riboflavin, folate, and vitamin C (65, 55, 54, and 53 percent, respectively). Within the same country and age groups, estimated inadequate intakes were higher for women with regards to iodine, vitamin B 12 , iron, and selenium, and for men with regards to magnesium, vitamin B 6 , zinc, vitamin C, vitamin A, thiamin, and niacin. "We hope this analysis sheds light on crucial nutrition challenges for locations without the necessary means to collect primary data, and improves understanding of global micronutrient inadequacy so that public health interventions can more effectively address deficiencies," the authors write. Abstract/Full Text Editorial Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

30 Aug 2024

·www.drugs.com

Billions of the World's People Deficient in Essential Micronutrients

FRIDAY, Aug. 30, 2024 -- More than half of people around the world aren’t getting enough micronutrients essential to human health, including calcium, iron and vitamins C and E, a new study says. These deficiencies are contributing to global malnutrition, as well as health problems like blindness, increased vulnerability to infections, and pregnancy complications, researchers said in The Lancet Global Health . “These results are alarming,” researcher Ty Beal , a senior technical specialist at the Global Alliance for Improved Nutrition, said in a news release. “Most people — even more than previously thought, across all regions and countries of all incomes — are not consuming enough of multiple essential micronutrients,” Beal said. “These gaps compromise health outcomes and limit human potential on a global scale.” For the study, researchers combined data from several sources to compare the nutritional intake of people in 185 countries. The team specifically assessed intake of 15 vitamins and minerals -- calcium, iodine, iron, riboflavin, folate, zinc, magnesium, selenium, thiamin, niacin, and vitamins A, B6 , B12, C and E. Researchers found widespread inadequate intake of iodine (68% of the world's population); vitamin E (67%); calcium (66%); and iron (65%). More than half of people consume inadequate levels of riboflavin, folate, and vitamins C and B6, researchers added. Intake of niacin was closest to sufficient, with 22% of people worldwide consuming too little, followed by thiamin (30%) and selenium (37%). “The public health challenge facing us is immense, but practitioners and policymakers have the opportunity to identify the most effective dietary interventions and target them to the populations most in need,” senior author Christopher Golden , associate professor of nutrition and planetary health at the Harvard T.H. Chan School of Public Health, said in a news release. Women were more likely than men to get too little iodine, vitamin B12, iron and selenium, results indicate. On the other hand, men weren't getting enough niacin, thiamin, zinc, magnesium, and vitamins A, C, and B6 compared to women, researchers said. Children and young adults 10 to 30 were most prone to low calcium intake, especially in South and East Asia and sub-Saharan Africa. Calcium intake was also low across North America, Europe and Central Asia. “Our study is a big step forward,” co-lead author Chris Free , a research professor at the University of California-Santa Barbara, said in a news release. “Not only because it is the first to estimate inadequate micronutrient intakes for 34 age-sex groups in nearly every country, but also because it makes these methods and results easily accessible to researchers and practitioners.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

100 Deals associated with Vitamin B2

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Vitamin B2	S01XA26	DB00140

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Riboflavin Deficiency	China	-	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Medium Chain Acyl CoA Dehydrogenase Deficiency	Preclinical	European Union	iniuva	08 Nov 2023
Astigmatism	Preclinical	United States	Glaukos Corp.	01 Aug 2013
Hyperopia	Preclinical	United States	Glaukos Corp.	01 Aug 2013
Corneal ectasia	Preclinical	-	Glaukos Corp.	01 Jul 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02863809 (CTgov)	Phase 1/2	Keratolysis	76	UVA Light Source+Dextran+Riboflavin (Active Treatment Arm)	ohafzyoxfo(ppozlbhyoy) = rbkmzedove tyozioixxa (zekcbbecjb, waorimsend - ylzkuzhjvl) View more	-	10 May 2023
				Dextran+Riboflavin (Control Treatment Arm)	ohafzyoxfo(ppozlbhyoy) = zikcbmvpql tyozioixxa (zekcbbecjb, wdfvgvfbfq - lofkxynmbs) View more
ARVO2023	Not Applicable	Keratoconus	18	Retention ring-assisted continuous riboflavin application	(cyasnwkogz) = mbezlkjbsb fdndsimdic (gjjrbtsqfe ) View more	-	23 Apr 2023
SSIEM2019	Not Applicable	-	-	Riboflavin 100mg/day	ispxpintht(gqussbrkti) = vygtuakvwv oynoerwaye (hxsxcmhohy )	-	25 Aug 2019
ARVO2019	Not Applicable	Keratoconus	168	Corneal collagen crosslinking with riboflavin and UV-A irradiation (CXL)	(hsclgpfzyy) = yjphnoowjb tugzgubsxb (fijlzvawkn ) View more	-	01 Jul 2019
2018 ARVO Annual Meeting (ARVO2018)	Not Applicable	Corneal ectasia	3	Riboflavin 400mg qd	snithtlgqg(tfjgfsqvul) = imnyxmlfdn jrmfcpgplw (gjfdlskxmz )	Positive	01 Jul 2018
				Riboflavin 400 mg BID or TID	snithtlgqg(tfjgfsqvul) = zckdybysxk jrmfcpgplw (gjfdlskxmz )
NCT01143389 (CTgov)	Phase 2	Keratoconus	510	UVX light+Riboflavin (Riboflavin 0.1% Eyedrops Every 5 Minutes)	fsvbnbpjlp(bihzjgslje) = kkfkzcfcaq wmrzwotxoz (lhjgekziwz, mxfcvuwnci - nxqiqfxoih) View more	-	04 May 2018
				UVX light+Riboflavin (Riboflavin 0.1% Eyedrops Every 2 Minutes)	fsvbnbpjlp(bihzjgslje) = wwtggyvljv wmrzwotxoz (lhjgekziwz, wnaxdmuexa - uqjamhffhu) View more
APAO2018	Not Applicable	Corneal ectasia	-	Riboflavin (OCT-guided femtosecond laser-assisted ICRS implantation)	vgakarcrbs(mbrkrmsuko) = fvgwsjgjpk xlmzwyqmvt (vluylwrbjj, 5.07)	-	08 Feb 2018
				Corneal collagen crosslinking with intracorneal riboflavin injection	vgakarcrbs(mbrkrmsuko) = xlravvxtua xlmzwyqmvt (vluylwrbjj, 6.33)
AAO2017	Not Applicable	-	20	Riboflavin 0.1% in HPMC-assisted CXL	(gdcacgekhs) = zzafghrbyu qkmfsocyba (cwelvjxuis )	-	13 Nov 2017
				Riboflavin 0.1% in dextran assisted with contact lens	(gdcacgekhs) = qkcchxllnv qkmfsocyba (cwelvjxuis )
NCT01582880 (CTgov)	Phase 1/2	Corneal Diseases \| Stevens-Johnson Syndrome \| Burns, Chemical \| Transplant complication \| Rheumatoid Arthritis \| Pemphigoid, Benign Mucous Membrane \| Systemic Lupus Erythematosus	1	Riboflavin	ftlbfjgghw(eezjcmxshw) = bsemarwewz ggitagrjhb (nrevjvphnd, opyaqpmgof - shhomrhslo) View more	-	24 Jul 2017
PO306 (AAO2015)	Not Applicable	-	-	RF-dextran	axyvprznee(qopqgdgrau) = veugmdzjdi fjygmyefrn (vyvryspfyi )	-	16 Nov 2015
				RF-HPMC	axyvprznee(qopqgdgrau) = ajixgxdoqx fjygmyefrn (vyvryspfyi )